Hospital
Mainehealth
Mainehealth was paid $22.62M by Medicaid between Jan 2018 and Jun 2024, across 355 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoMAINEHEALTH
FARMINGTON, ME 04938
FARMINGTON, ME 04938
33aNPI1558305847assigned 06/16/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.62M
24GClaims746,795
24DCodes billed355
24AFirst – last monthJan 2018 – Jun 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maine
Rank by total paid#10 of 33
Median peer was paid$4.34M
This provider vs. median5.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official INZANA, LUGENE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 130,039 | $3.58M | |
| 2019 | 117,866 | $3.29M | |
| 2020 | 84,547 | $2.35M | |
| 2021 | 109,879 | $3.11M | |
| 2022 | 115,337 | $3.48M | |
| 2023 | 123,483 | $4.24M | |
| 2024incomplete | 65,644 | $2.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 19,931 | 18,120 | $3.32M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 12% | 50,787 | 36,552 | $2.78M |
| A0425 | Ground mileage, per statute mile | 8.2% | 18,075 | 13,671 | $1.86M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.4% | 12,456 | 11,850 | $1.44M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.1% | 4,636 | 4,326 | $1.38M |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 5.9% | 6,711 | 5,940 | $1.34M |
| A0429 | Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency) | 3.6% | 4,343 | 3,788 | $824K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 2.6% | 5,371 | 4,373 | $588K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.5% | 6,200 | 5,536 | $567K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 7,214 | 6,825 | $565K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 22,243 | 8,046 | $508K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 3,354 | 3,215 | $422K |
343 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 5,297 | $354K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 7,443 | $274K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 1,811 | $260K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.0% | 3,101 | $237K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 6,780 | $233K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,797 | $213K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,019 | $208K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,703 | $185K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,013 | $178K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,329 | $170K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,675 | $158K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,885 | $157K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,159 | $145K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,704 | $143K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,619 | $128K |
| A0434 | Specialty care transport (sct) | <1% | 283 | $126K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,270 | $115K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,050 | $106K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 910 | $104K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,528 | $101K |
| 80053 | Comprehensive metabolic panel | <1% | 37,785 | $100K |
| 97161 | <1% | 2,739 | $98K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,375 | $93K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 208 | $90K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,205 | $90K |
| 80061 | Lipid panel | <1% | 12,233 | $90K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,009 | $88K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,633 | $82K |
| 94060 | <1% | 815 | $79K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 918 | $77K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,134 | $76K |
| 86900 | <1% | 1,795 | $76K | |
| 76830 | Ultrasound, transvaginal | <1% | 996 | $72K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,834 | $67K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,833 | $67K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,565 | $64K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,420 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,905 | $60K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,967 | $56K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,784 | $52K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 280 | $52K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 11,938 | $49K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 404 | $48K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 497 | $48K |
| 97162 | <1% | 1,466 | $47K | |
| 87481 | <1% | 2,055 | $43K | |
| 73630 | <1% | 2,184 | $42K | |
| 76770 | <1% | 652 | $39K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 7,024 | $38K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 127 | $37K |
| 73564 | <1% | 1,685 | $36K | |
| 73030 | <1% | 2,028 | $36K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 46,742 | $32K |
| 73610 | <1% | 1,707 | $31K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,984 | $29K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,284 | $28K |
| 71250 | <1% | 697 | $27K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 485 | $26K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,464 | $25K |
| 0012A | <1% | 1,565 | $24K | |
| 72100 | <1% | 684 | $24K | |
| 80306 | <1% | 6,444 | $24K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,668 | $24K |
| 20610 | <1% | 312 | $23K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,140 | $22K |
| 0011A | <1% | 1,571 | $22K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 271 | $22K |
| 73110 | <1% | 1,216 | $21K | |
| 88142 | <1% | 1,530 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,655 | $21K |
| 87511 | <1% | 1,055 | $21K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,567 | $21K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 71 | $20K |
| 73130 | <1% | 1,222 | $20K | |
| 76642 | <1% | 440 | $20K | |
| 90837 | Psychotherapy session, about an hour | <1% | 316 | $19K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,055 | $19K |
| 83655 | <1% | 2,040 | $19K | |
| 82728 | <1% | 3,014 | $19K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 334 | $18K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,384 | $18K |
| 93971 | <1% | 339 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,477 | $17K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 800 | $17K |
| 82607 | <1% | 2,362 | $16K | |
| 87070 | <1% | 4,606 | $16K | |
| 73502 | <1% | 961 | $16K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 393 | $16K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 24 | $16K |
| 86803 | <1% | 2,249 | $15K | |
| 86780 | <1% | 1,216 | $14K | |
| 96161 | <1% | 784 | $13K | |
| 80305 | <1% | 1,908 | $13K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 161 | $13K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 153 | $13K |
| 74018 | <1% | 558 | $12K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 253 | $12K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 199 | $11K |
| 81025 | <1% | 3,254 | $11K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 376 | $11K |
| 85610 | <1% | 8,603 | $10K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,182 | $10K |
| 71271 | <1% | 206 | $10K | |
| 84439 | <1% | 1,891 | $9K | |
| 83550 | <1% | 2,371 | $9K | |
| 82746 | <1% | 1,358 | $9K | |
| 90686 | <1% | 2,504 | $9K | |
| 96127 | <1% | 1,896 | $9K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 392 | $8K |
| 73562 | <1% | 255 | $8K | |
| 96160 | <1% | 361 | $8K | |
| 83735 | <1% | 11,113 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 55 | $8K |
| 83540 | <1% | 2,666 | $8K | |
| 70496 | <1% | 55 | $8K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 103 | $8K |
| 97803 | <1% | 239 | $8K | |
| 85027 | <1% | 3,344 | $7K | |
| 11721 | <1% | 890 | $7K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 354 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 337 | $7K |
| 83970 | <1% | 488 | $7K | |
| 87186 | <1% | 3,134 | $7K | |
| 76536 | <1% | 112 | $7K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 17 | $6K |
| 86140 | <1% | 4,841 | $6K | |
| A0433 | Advanced life support, level 2 (als 2) | <1% | 13 | $5K |
| 82043 | <1% | 2,392 | $5K | |
| 93017 | <1% | 186 | $5K | |
| 81003 | <1% | 7,441 | $5K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 659 | $5K |
| 73140 | <1% | 185 | $5K | |
| 87077 | <1% | 3,234 | $5K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 81 | $5K |
| 86618 | <1% | 811 | $5K | |
| 81001 | <1% | 9,780 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 918 | $5K |
| 90670 | <1% | 1,177 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 19 | $4K |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | <1% | 17 | $4K |
| 97166 | <1% | 170 | $4K | |
| 97802 | <1% | 75 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 52 | $4K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 182 | $4K |
| 29581 | <1% | 97 | $4K | |
| 84403 | <1% | 220 | $4K | |
| 96367 | <1% | 157 | $4K | |
| 52000 | <1% | 46 | $4K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 100 | $4K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 12 | $4K |
| 72110 | <1% | 100 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 492 | $4K |
| 83880 | <1% | 1,701 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,216 | $3K |
| 94726 | <1% | 178 | $3K | |
| 85018 | <1% | 2,413 | $3K | |
| 84153 | <1% | 530 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 84 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 224 | $3K |
| 87340 | <1% | 1,082 | $3K | |
| 85652 | <1% | 3,192 | $3K | |
| 90473 | <1% | 311 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 180 | $2K |
| 83690 | <1% | 4,776 | $2K | |
| 80050 | General health panel | <1% | 104 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 147 | $2K |
| 73080 | <1% | 105 | $2K | |
| 87088 | <1% | 1,655 | $2K | |
| 17110 | <1% | 41 | $2K | |
| 84702 | <1% | 420 | $2K | |
| 86038 | <1% | 300 | $2K | |
| 87469 | <1% | 236 | $2K | |
| 87468 | <1% | 236 | $2K | |
| 96415 | <1% | 38 | $2K | |
| 82950 | <1% | 382 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 405 | $2K |
| 88304 | <1% | 183 | $2K | |
| 0002A | <1% | 42 | $2K | |
| 82784 | <1% | 370 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 62 | $1K |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 98 | $1K |
| 76801 | <1% | 16 | $1K | |
| 84100 | <1% | 1,385 | $1K | |
| 82570 | <1% | 797 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 37 | $1K |
| 72040 | <1% | 44 | $1K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 168 | $1K |
| D1206 | Topical application of fluoride varnish | <1% | 124 | $1K |
| 73590 | <1% | 121 | $1K | |
| 90732 | <1% | 42 | $1K | |
| 83921 | <1% | 176 | $1K | |
| 77080 | <1% | 73 | $1K | |
| 97165 | <1% | 40 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,737 | $1K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 985 | $1K |
| 99223 | Prolong inpt eval add15 m | <1% | 15 | $1K |
| 80076 | <1% | 271 | $976.44 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 109 | $938.69 |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 13 | $881.53 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,726 | $880.49 |
| 86762 | <1% | 562 | $867.29 | |
| 36591 | <1% | 58 | $850.74 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 45 | $847.99 |
| 84703 | <1% | 3,169 | $847.11 | |
| 99177 | <1% | 274 | $828.00 | |
| 87522 | Neg quan hep c or qual rna | <1% | 25 | $709.83 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,436 | $708.22 |
| 90651 | <1% | 414 | $688.16 | |
| 87081 | <1% | 879 | $668.09 | |
| 87205 | <1% | 686 | $655.76 | |
| 87210 | <1% | 370 | $644.98 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,224 | $642.53 |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 13 | $642.07 |
| 80081 | <1% | 14 | $632.42 | |
| G0378 | Hospital observation service, per hour | <1% | 993 | $614.34 |
| 85730 | <1% | 805 | $606.96 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,247 | $593.11 |
| 86850 | <1% | 1,825 | $590.37 | |
| 86706 | <1% | 76 | $584.55 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,459 | $516.93 |
| 0001A | <1% | 15 | $510.51 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 28 | $475.22 |
| 87040 | <1% | 1,484 | $471.47 | |
| 76870 | <1% | 12 | $462.28 | |
| 82550 | <1% | 512 | $459.59 | |
| 84484 | <1% | 8,130 | $446.06 | |
| 86364 | <1% | 60 | $444.74 | |
| 87400 | <1% | 526 | $442.98 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,383 | $429.15 |
| 85379 | <1% | 1,461 | $427.69 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,096 | $422.33 |
| 93242 | <1% | 42 | $419.40 | |
| 0064A | <1% | 67 | $391.80 | |
| 87420 | <1% | 299 | $389.61 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 12 | $384.48 |
| 93225 | <1% | 14 | $381.64 | |
| 84156 | <1% | 270 | $355.71 | |
| 84460 | <1% | 125 | $351.94 | |
| 87147 | <1% | 212 | $328.27 | |
| 84550 | <1% | 173 | $319.99 | |
| 92583 | <1% | 16 | $315.36 | |
| 88112 | <1% | 14 | $304.97 | |
| 70498 | <1% | 72 | $297.76 | |
| 83605 | <1% | 2,223 | $293.81 | |
| 90734 | <1% | 446 | $292.47 | |
| 84146 | <1% | 25 | $291.23 | |
| 84402 | <1% | 17 | $288.93 | |
| 73090 | <1% | 30 | $286.88 | |
| 82948 | <1% | 5,931 | $277.50 | |
| 80069 | <1% | 100 | $268.67 | |
| 88342 | <1% | 12 | $245.12 | |
| 51798 | <1% | 65 | $240.66 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 159 | $238.86 |
| 86431 | <1% | 70 | $228.12 | |
| 90715 | <1% | 1,463 | $207.93 | |
| 85014 | <1% | 289 | $180.45 | |
| 81002 | <1% | 172 | $177.00 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $169.38 |
| 99188 | <1% | 27 | $168.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,752 | $154.82 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 464 | $150.00 |
| 82565 | <1% | 124 | $149.45 | |
| 80164 | <1% | 24 | $147.94 | |
| 90662 | <1% | 165 | $123.23 | |
| 82805 | <1% | 292 | $116.00 | |
| 51741 | <1% | 29 | $108.15 | |
| 97116 | <1% | 18 | $102.31 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 356 | $100.00 |
| 86901 | <1% | 1,888 | $96.25 | |
| 86200 | <1% | 14 | $95.99 | |
| 84450 | <1% | 30 | $94.51 | |
| 73552 | <1% | 13 | $90.66 | |
| 93226 | <1% | 14 | $81.67 | |
| 90716 | <1% | 188 | $81.67 | |
| 83615 | <1% | 79 | $72.48 | |
| 83721 | <1% | 13 | $67.13 | |
| 87071 | <1% | 18 | $57.84 | |
| 85378 | <1% | 170 | $50.87 | |
| 94729 | <1% | 285 | $48.97 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 15 | $46.44 |
| 0072A | <1% | 97 | $39.27 | |
| 81015 | <1% | 31 | $37.68 | |
| 82150 | <1% | 111 | $32.60 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 52 | $31.81 |
| 82272 | <1% | 50 | $27.53 | |
| 90744 | <1% | 233 | $26.92 | |
| 86308 | <1% | 28 | $26.45 | |
| 36416 | <1% | 1,925 | $23.31 | |
| 74022 | <1% | 46 | $22.47 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 631 | $15.63 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 147 | $10.76 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 770 | $8.57 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 477 | $7.63 |
| 96376 | <1% | 1,062 | $6.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,938 | $5.63 |
| 82140 | <1% | 13 | $5.00 | |
| 85007 | <1% | 36 | $2.46 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,300 | $0.02 |
| 90648 | 0% | 229 | $0.00 | |
| 90710 | 0% | 135 | $0.00 | |
| 90707 | 0% | 159 | $0.00 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 2,145 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 660 | $0.00 |
| 90633 | 0% | 656 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 61 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 255 | $0.00 |
| 87806 | 0% | 19 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 431 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 249 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 47 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 55 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 322 | $0.00 |
| 0071A | 0% | 126 | $0.00 | |
| 69209 | 0% | 13 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 15 | $0.00 |
| 90685 | 0% | 211 | $0.00 | |
| 91300 | 0% | 49 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 22 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 14 | $0.00 |
| 90723 | 0% | 204 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 1,039 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 118 | $0.00 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | 0% | 31 | $0.00 |
| 94760 | 0% | 418 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,149 | $0.00 |
| 90680 | 0% | 680 | $0.00 | |
| 90474 | 0% | 313 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 30 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 327 | $0.00 |
| 90698 | 0% | 750 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 60 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 29 | $0.00 |
| 91301 | 0% | 1,341 | $0.00 | |
| 90696 | 0% | 129 | $0.00 | |
| 86317 | 0% | 71 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 14 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 336 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 28 | $0.00 |
| J3490 | Unclassified drugs | 0% | 70 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 15 | $0.00 |
| 82803 | 0% | 29 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 29 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialINZANA, LUGENE (SVP FINANCE, CFO)
Parent organizationMAINEHEALTH
| Provider | Location | Paid |
|---|---|---|
| Mainehealth | Portland, ME | $142.72M |
| Mainehealth | Portland, ME | $115.05M |
| Mainehealth | Biddeford, ME | $70.83M |
| Mainehealth | Brunswick, ME | $40.06M |
| Mainehealth | Biddeford, ME | $10.89M |
| Mainehealth | Falmouth, ME | $6.54M |
| Mainehealth | Portland, ME | $5.46M |
| Mainehealth | Scarborough, ME | $5.04M |
| Mainehealth | Rockport, ME | $4.34M |
| Mainehealth | Scarborough, ME | $4.16M |
| Mainehealth | Portland, ME | $4.09M |
| Mainehealth | Scarborough, ME | $3.94M |
| Mainehealth | Portland, ME | $3.55M |
| Mainehealth | Waldoboro, ME | $3.43M |
| Mainehealth | Scarborough, ME | $3.18M |
| Mainehealth | Brunswick, ME | $2.77M |
| Mainehealth | Portland, ME | $2.68M |
| Mainehealth | Falmouth, ME | $2.10M |
| Mainehealth | Portland, ME | $1.87M |
| Mainehealth | Cape Elizabeth, ME | $1.82M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.